GENELUX Corp
Developing oncolytic viral immunotherapies for difficult-to-treat cancers using a vaccinia virus.
GNLX | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 2625 TOWNSGATE ROAD, SUITE 230, 91361 WESTLAKE VILLAGE
- Website:
- https://genelux.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Genelux Corporation is a late clinical-stage biopharmaceutical company developing next-generation oncolytic viral immunotherapies for patients with difficult-to-treat cancers. The company's core technology is a therapeutics and diagnostics platform based on a proprietary, highly customizable vaccinia virus (VACV) backbone. Its lead clinical candidate, Olvi-Vec, is a modified oncolytic vaccinia virus undergoing a registrational Phase 3 trial for platinum-resistant/refractory ovarian cancer. Product development is accelerated by the proprietary CHOICE™ discovery platform, which enables the rapid generation of new viral candidates. Genelux aims to create versatile, "off-the-shelf" immunotherapies with systemic administration potential for a broad range of solid and metastatic tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all GENELUX Corp filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GENELUX Corp
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GENELUX Corp via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
